News & Updates

Adding once-daily subcutaneous liraglutide to lifestyle interventions reduces BMI in children aged 6 to <12 years with obesity, according to the SCALE Kids trial presented at EASD 2024.

Disorders of gut-brain interaction during childhood may continue until adulthood in some patients, reveals a study, noting that management monitoring should persist into adulthood.

A longitudinal study from KK Women’s and Children’s Hospital (KKH) shows that women who exclusively breastfed at 6 and 12 months postpartum are at a lower risk for substantial postpartum weight retention (PPWR; defined as weight retention of ≥5 kg) compared with those who exclusively formula-fed their infants or practiced a mix of both.

For young children with an upper respiratory tract infection, also known as common cold, treatment with hypertonic saline nasal drops is safe and beneficial, shortening recovery time by 2 days and, in turn, reducing household spread of the disease, according to the results of the ELVIS-Kids trial.

New drug applications approved by US FDA as of 16-31 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The novel oral corticotropin-releasing factor type 1 receptor antagonist crinecerfont helps supress androstenedione levels in children with congenital adrenal hyperplasia (CAH) and reduce the need for glucocorticoids, as shown in the phase III CAHtalyst Pediatric trial.